Enhanced immune response after a second dose of an AS03-adjuvanted H1N1 influenza A vaccine in patients after hematopoietic stem cell transplantation

Seroconversion rates following influenza vaccination in patients with hematologic malignancies after hematopoietic stem cell transplantation (HSCT) are known to be lower compared to healthy adults. The aim of our diagnos
Seroconversion rates following influenza vaccination in patients with hematologic malignancies after hematopoietic stem cell transplantation (HSCT) are known to be lower compared to healthy adults. The aim of our diagnostic study was to determine the rate of seroconversion after 1 or 2 doses of a novel split virion, inactivated, AS03-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in HSCT recipients (ClinicalTrials.gov Identifier: NCT01017172). Blood samples were taken before and 21 days after a first dose and 21 days after a second dose of the vaccine. Antibody (AB) titers were determined by hemagglutination inhibition assay. Seroconversion was defined by either an AB titer of ≤1:10 before and ≥1:40 after or ≥1:10 before and ≥4-fold increase in AB titer 21 days after vaccination. Seventeen patients (14 allogeneic, 3 autologous HSCT) received 1 dose and 11 of these patients 2 doses of the vaccine. The rate of seroconversion was 41.2% (95% confidence interval [CI] 18.4-67.1) after the first and 81.8% (95% CI 48.2-97.7) after the second dose. Patients who failed to seroconvert after 1 dose of the vaccine were more likely to receive any immunosuppressive agent (P = .003), but time elapsed after or type of HSCT, age, sex, or chronic graft-versus-host disease was not different when compared to patients with seroconversion. In patients with hematologic malignancies after HSCT the rate of seroconversion after a first dose of an adjuvanted H1N1 influenza A vaccine was poor, but increased after a second dose.
show moreshow less

Download full text files

Export metadata

  • Export Bibtex
  • Export RIS
Metadaten
Author:Saskia Güller, Regina Allwinn, Sabine Mousset, Hans Martin, Imke Wieters, Eva Herrmann, Hubert Serve, Markus Bickel, Gesine Bug
URN:urn:nbn:de:hebis:30:3-445145
DOI:http://dx.doi.org/10.1016/j.bbmt.2011.02.004
ISSN:1523-6536
ISSN:1083-8791
Pubmed Id:http://www.ncbi.nlm.nih.gov/pubmed?term=21324375
Parent Title (English):Biology of blood and marrow transplantation
Publisher:Elsevier Health Sciences
Place of publication:[s. l.]
Document Type:Article
Language:English
Date of Publication (online):2017/11/09
Year of first Publication:2011
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2017/11/09
Tag:H1N1; HSCT; Hemagglutination inhibition assay
Volume:17
Issue:10
Pagenumber:5
First Page:1546
Last Page:1550
Note:
Copyright © 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. Under a Creative Commons license
HeBIS PPN:426712455
Institutes:Medizin
Dewey Decimal Classification:610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (German):License LogoCreative Commons - Namensnennung-Nicht kommerziell - Keine Bearbeitung 4.0

$Rev: 11761 $